Komori
KYORIN Pharmaceutical (4569) · InitiativeRestated

Rebuilding the Human Resources Management System and Strengthening Talent Development

First written in FY2017. 5 of 9 entries say "Restated". Latest entry: FY2026.

9entries
10years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2017 – FY2019ReframedFY2020 – FY2023RestatedFY2024-Q2 – FY20242017: 120172018: 120182019: 120192020: 120202021: 020212022: 020222023: 220232024: 120242025: 120252026: 12026
Same theme, other companies
Human Capital Development and Employee EngagementA theme 53 companies write about · 0 as a headwind · 53 as a tailwind

KYORIN Pharmaceutical moved to the "Worse" side of this theme in 2020, 5 years before the typical company in this theme (2025).

The whole theme swung hardest in 2020: 3 of 9 companies on the "Worse" side.

7 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 53 companies compared. The sentences above are computed from all 53.
Full recordFilings, disclosures and news, newest first
  1. FY2026RestatedAnnual report

    「In the annual employee engagement survey conducted by each group company, the company aims to raise the key scores, while gathering opinions on the talent management system and reviewing and improving the system.」

    The company continues to strengthen its human capital by improving the key scores in its engagement survey and reviewing and improving its talent systems.
  2. FY2025AdvancedAnnual report

    「To strengthen its human capital, the company revised and implemented new personnel systems, promoted talent development and work-style reform to accommodate diverse perspectives, and also actively addressed environmental issues, compliance and corporate governance.」

    To strengthen its human capital, the company implemented the revision and operation of new personnel systems, talent development and work-style reform, in addition to building and operating its existing talent management system.
  3. FY2024RestatedAnnual report

    「Based on the basic concept of its talent management system that the company and its employees are partners who realise mutual benefits by continuously fulfilling, over the long term, the responsibilities expected of them by each other, with employees contributing to the company's development and the company contributing to employees' enriched lives and self-realisation, the group will build and appropriately operate systems, including policies, standards and regulations, for recruitment, placement, growth and development, evaluation, transfers, compensation and benefits.」

    The company continues to position strengthening its human capital as a driver of business growth and to build and operate a talent management system covering recruitment, development, evaluation and compensation.
  4. FY2024-Q2RestatedAnnual report

    「Under Vision 110 –Stage1–, the company is vigorously transforming its business structure, promoting measures including strengthening its ability to create high-value new drugs that meet medical needs, expanding its development pipeline through in-licensing, and maximising the proportion of new drugs. As part of building a sustainable corporate foundation, it is also working to strengthen its human capital.」

    The company continues to pursue building a sustainable corporate foundation and strengthening its human capital in Stage1.
  5. FY2023ReframedAnnual report

    「Based on the founder's belief that business is built on people, our group considers the growth of its people to be the driving force behind business growth and is working to strengthen its human capital.」

    The company has reorganised its previous focus on rebuilding the talent management system and strengthening talent development into initiatives covering human capital, respect for human rights, diversity, and a healthy and safe workplace environment.
  6. FY2020ReframedAnnual report

    「In Stage 3, the company also aims to realise the No. 1 company to work for among its employees. Under its basic talent management policy, it will promote work-style reform and strengthen the development and recruitment of next-generation talent.」

    The company has developed its previous policy of rebuilding the talent management system and strengthening development into a Stage 3 organisational strategy by adding work-style reform and the development and recruitment of next-generation talent.
  7. FY2019RestatedAnnual report

    「We will rebuild the human resources management systems of each Group company, covering recruitment, placement, development, evaluation, transfers, compensation and benefits, and strengthen talent development.」

    The company continues to rebuild its talent management system and strengthen talent development.
  8. FY2018RestatedAnnual report

    「We will rebuild the human resources management systems of each Group company, covering recruitment, placement, development, evaluation, transfers, compensation and benefits, and strengthen talent development.」

    The company continues to rebuild its talent management system and strengthen talent development.
  9. FY2017First statedAnnual report

    「We will rebuild the human resources management systems of each Group company, covering recruitment, placement, development, evaluation, transfers, compensation and benefits, and strengthen talent development.」

    The Group identifies rebuilding human resources management systems from recruitment through benefits, together with stronger talent development, as a specific initiative.
Moved together

"Decline in Upfront License Fees and Royalty Income" moved the same way as this thread, in the same document, in 2 of its 9 moves.

222★123
  1. ★This thread
  2. 1Decline in Upfront License Fees and Royalty Income2×
  3. 2Diversifying Business Risk through a Combination of the Prescription Pharmaceutical and Healthcare Businesses2×
  4. 3Impact of Foreign Exchange Rate Movements on Business Results2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for KYORIN Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Rebuilding the Human Resources Management System and Strengthening Talent Development | KYORIN Pharmaceutical Co.,Ltd. (4569) | Komori